Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma 6Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Burkitt Lymphoma 3Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Waldenstrom Macroglobulinemia 1Recurrence 1Paraproteinemias 1Neoplasms 1Lymphoproliferative Disorders 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

dacetuzumab 2Bortezomib 2epratuzumab 1edoxaban 1Vorinostat 1Tranexamic Acid 1Saline Solution 1Lenalidomide 1Enoxaparin 1Dipyrone 1Dexamethasone 1Calcium Dobesilate 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hemostatic Disorders × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡